USE OF CCI-779 AS ANTINEOPLASTIC AGENT

摘要

PROBLEM TO BE SOLVED: To provide the use of CCI-779 as an antineoplastic agent, and particularly for neoplasms which are refractory to standard therapy, or for patients for whom standard therapy is not appropriate.SOLUTION: The present invention provides pharmaceutical compositions containing rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) for use in treatment of refractory renal cell cancer in a mammal in which a neoplasm progressed following treatment with standard chemotherapy appropriate for the neoplasm.SELECTED DRAWING: None